Imunon reports 2023 net loss $19.5M; OVATION 2 shows ~30% PFS delay, ~9 months OS improvement

Imunon, Inc.

Net loss $19.5M ($2.16 per share) vs $35.9M ($5.03 per share) in 2022; operating expenses down 17%.
Cash, investments and accrued interest $15.7M at year end; expects funding into Q4 2024.
Interim OVATION 2 data: ~30% delay in disease progression or death; ~9 month OS improvement in treatment arm vs control.
Phase 1/2 trial of IMNN-001 + bevacizumab enrolling at MD Anderson and MSK.
PlaCCine COVID-19 booster IND submitted; Phase 1 proof-of-concept expected Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.